Bayer plans $2.2 billion pharmaceutical facility in US
German company Bayer has announced plans to invest $2.2 billion in a new pharmaceutical production facility in the United States.
The investment, equivalent to €1.95 billion, would expand the company’s manufacturing presence in the US through a new site dedicated to medicines.
The announcement comes amid pressure from President Donald Trump’s administration on pharmaceutical companies to increase production on American soil.
Bayer’s planned facility places it among drugmakers facing that push toward domestic manufacturing. The announcement did not specify whether the administration’s pressure directly influenced the investment decision.
This is an automated summary from the available headline and excerpt, not the full story or a claim of human review.
Latest Economy — refreshed every 30 minutes
News refreshes automatically every 30 minutes. Every headline opens inside Trend Masr.